| Literature DB >> 28686014 |
Che Fu Liu1, Raymond Chen1, Joseph A Frezzo1, Priya Katyal1, Lindsay K Hill1,2,3, Liming Yin1, Nikita Srivastava1, Haresh T More1, P Douglas Renfrew4, Richard Bonneau5,6,4, Jin Kim Montclare1,7,8.
Abstract
An engineered supercharged coiled-coil protein (CSP) and the cationic transfection reagent Lipofectamine 2000 are combined to form a lipoproteoplex for the purpose of dual delivery of siRNA and doxorubicin. CSP, bearing an external positive charge and axial hydrophobic pore, demonstrates the ability to condense siRNA and encapsulate the small-molecule chemotherapeutic, doxorubicin. The lipoproteoplex demonstrates improved doxorubicin loading relative to Lipofectamine 2000. Furthermore, it induces effective transfection of GAPDH (60% knockdown) in MCF-7 breast cancer cells with efficiencies comparing favorably to Lipofectamine 2000. When the lipoproteoplex is loaded with doxorubicin, the improved doxorubicin loading (∼40 μg Dox/mg CSP) results in a substantial decrease in MCF-7 cell viability.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28686014 DOI: 10.1021/acs.biomac.7b00203
Source DB: PubMed Journal: Biomacromolecules ISSN: 1525-7797 Impact factor: 6.988